Boehringer Exercises Option Under Oxford Bio Alliance

Boehringer Ingelheim has exercised an option for exclusive rights to an oncology target from its discovery collaboration with Oxford BioTherapeutics. The target was discovered using Oxford’s OGAP system, which incorporates one of the world’s largest proteomic databases, integrating clinical, experimental and expression data.  
 
This represents the second option exercised under the companies’ oncology target discovery and validation collaboration established in 2013. Under the agreement, Boehringer is responsible for the future development and commercialization of antibody products to the target. Oxford will receive development and regulatory milestone payments, and royalties on any future product sales.  
 
Dr. Christian Rohlff, chairman and chief executive officer of Oxford BioTherapeutics, said, “Boehringer Ingelheim is one of the world’s leading oncology companies and their decision to exercise an option on a second target is a further significant endorsement of our unique OGAP discovery platform.  As interest in antibody therapeutics continues to grow, Oxford BioTherapeutics is rapidly establishing itself as a partner of choice for the development of next generation cancer treatments, supported by our world-leading targeting technology and in-house pipeline of novel antibody-drug conjugates.”